Teduglutide for treating short bowel syndrome

2.1 Teduglutide (Revestive, Takeda) is 'indicated for the treatment of patients aged 1 year and above with short bowel syndrome (SBS). Patients should be stable following a period of intestinal adaptation after surgery.'

2.2 The dosage schedule is available in the summary of product characteristics for teduglutide.

2.3 The list price of a 5 mg vial of teduglutide is £521.98. The list price of a 1.25 mg vial of teduglutide is £260.99 (excluding VAT; BNF online, accessed April 2022).

2.4 The company has a commercial arrangement. This makes teduglutide available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.